Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group announced that its new drug application for Efmedaglutide Alfa Injection, aimed at long-term weight management in overweight or obese adults, has been accepted by China’s National Medical Products Administration. This acceptance, based on successful Phase III clinical trials, highlights the drug’s efficacy in reducing body weight and improving cardiovascular and metabolic parameters, with a favorable safety profile. The company is also conducting further trials for type 2 diabetes, potentially expanding its impact on patient care.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company specializing in the pharmaceutical industry. It focuses on developing and manufacturing therapeutic biological products, with a market emphasis on innovative treatments for various health conditions.
YTD Price Performance: 101.99%
Average Trading Volume: 171,345,986
Technical Sentiment Signal: Buy
Current Market Cap: HK$109.6B
See more data about 1093 stock on TipRanks’ Stock Analysis page.